PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.01
Negative OCF/share while Biotechnology median is -0.14. Seth Klarman would examine if a turnaround is realistic.
-0.01
Negative FCF/share while Biotechnology median is -0.17. Seth Klarman would question if the business is too capex-heavy.
No Data
No Data available this quarter, please select a different quarter.
1.00
Ratio 1.25–1.5x Biotechnology median of 0.77. Mohnish Pabrai would confirm that earnings truly convert to cash better than peers.
No Data
No Data available this quarter, please select a different quarter.